Decoy Therapeutics is trading at $5.92 (+132.61%) after announcing a pan-filovirus program using the FDA Animal Rule pathway on September 22, 2026.
- Reported preclinical activity against Ebola Zaire and Marburg viruses.
- Pursuing non-dilutive grants and public-health partnerships.
- Potential Priority Review Voucher monetization added speculative appeal; the release did not explicitly cite stock-market reaction.